Free Health Testing For Sandwell Residents As Council Partner With Randox Health To Detect Early Warning Signs of Serious Illness

Home - Kidney

Free Health Testing For Sandwell Residents As Council Partner With Randox Health To Detect Early Warning Signs of Serious Illness

Sandwell Council partners with Randox Health to launch free health checks service

Sandwell Council initiative places prevention at the centre of healthcare

Thousands of eligible Sandwell residents are being offered diagnostic NHS Health Checks to detect any early signs of diabetes, heart and kidney disease and hypertension.

The early identification of individuals with the potential to develop these conditions will enable the NHS to intervene and, in many cases, prevent the onset of potentially life-changing and life-threatening illnesses.

In a pioneering initiative, the Sandwell tests and online self-assessment provision will be provided by a partnership comprising the council’s Healthy Sandwell team, the NHS and diagnostics company Randox Health – whose tests and clinics will be used to facilitate the innovative testing. Tests and clinics will be available for Sandwell residents in both Sandwell and, if convenient, in Birmingham.

The awarding of the contract to Randox Health to provide the tests follows an open tender process by Sandwell Council. The company has demonstrated success in providing 17 million PCR tests to NHS Test and Trace during the Covid-19 pandemic, helping prevent thousands of hospitalisations and deaths in the UK.

Free tests will be offered to Sandwell residents aged between 40 and 74 who have not previously suffered coronary heart disease, strokes, diabetes or kidney disease. Each will, in the next few weeks, begin receiving letters inviting them to the 20-minute NHS check, with branding from Randox, Healthy Sandwell and the NHS. The letter will include a link to the Randox website through which the tests can be booked.

Sandwell residents who have not yet received a GP letter and believe they are eligible can visit the Randox website https://nhshealthcheck.randox.com, take an eligibility check and then book their own appointment.

Tests will be carried out by specially trained staff at a number of community pop-up clinics in locations in Sandwell such as leisure centres and community spaces, aiming to reach those most at risk of having an undiagnosed serious illness.

Tests for Sandwell residents will also be available at Randox Health’s Birmingham Clinic (39-40 High Street, B4 7SL).

Test results will be made available to GPs for inclusion on patient medical records through Health Diagnostics Ltd, a third-party provider. Randox will hold none of the data from the test results.

Not only will the testing programme enable prevention and mitigation through the early identification of serious illness, it will also allow lifestyle modification on issues including smoking, alcohol and weight management.

Councillor Suzanne Hartwell, Sandwell Council’s Cabinet Member for Adults, Social Care & Health, said:

“The good health of our residents has always been a priority for the Council. This initiative will have a significant and beneficial impact on the health and longevity of thousands of people living in the area. It will enable those at high risk to take medical and lifestyle steps to prevent illnesses which could, if not detected early, shorten or change lives.” 

 

David Ferguson, Chief Operating Officer for Randox Health said:

 

“Randox is delighted to be part of this joint initiative with Sandwell Council’s Public Health Team. It has long been our belief that early diagnostic health testing delivers better outcomes for individuals. It relieves the pressure on our NHS by enabling lifestyle change and medical intervention. This, in turn, prevents or mitigates illnesses which would otherwise require intense long-term treatment.”    

 

 

Editors Notes

1. Sandwell Council  

Sandwell Council will participate in the partnership through Healthy Sandwell, which is part of the council’s Public Health team.  Healthy Sandwell provides a range of services to support local people to make positive lifestyle changes, such as quitting smoking or losing weight. Further information: https://www.healthysandwell.co.uk/

2. Randox Health

Established in 1982, Randox is the largest healthcare diagnostics company from the UK and Ireland.

Undertaking research, development, manufacture and distribution of innovative laboratory tests and analysers, Randox provides 15% of all worldwide cholesterol tests and 10% of all clinical chemistry tests. More than 5% of the world’s population (over 370 million people) receive medical diagnosis using Randox products each year.

Randox Health focuses on the provision of timely and accurate testing to identify risk to health, improve clinical diagnoses and promote preventative healthcare; aiming to achieve better healthcare outcomes whilst reducing the burden on clinical services.

In early 2020 Randox recognised the threat from COVID-19 and quickly developed a test to accurately identify the virus.  Testing at scale commenced within weeks to support the UK’s National Testing Programme and private clients. Randox has processed more than 25 million gold-standard PCR tests for the National Testing Programme and private COVID testing for travel.

Randox Health is clear that better diagnostics are unquestionably critical to future improvements within healthcare and is committed to remaining at the forefront of that field.

Its growing network of High Street clinics now operate in 20 locations around the UK and Ireland, including Birmingham.


World Kidney Day 2021

World Kidney Day 2021

11th March 2021 is World Kidney Day, a worthy global campaign aimed at tackling “the hot topic everyone’s ignoring”.

Raising awareness of a disease that ‘one in every nine’ people worldwide suffer from, is something we take seriously.

Here at Randox, our vision is to improve healthcare worldwide and ensure patients across the globe have access to the latest advancements in clinical diagnostics to tackle diseases such as Chronic Kidney Disease.

This year World Kidney Day 2021 focuses on being able to live well with kidney disease. Many of us take for granted being able to live a normal life without the side effects such as fatigue, pain, depression, sleep problems etc. However Kidney disease can be huge challenge patients and those around them. The impacts of kidney disease can take a toll of day to day life and the ability to participate in activities such as work, travel, and socialising.

Kidney diseases are very common and can be harmful, but the good news is they are also very treatable!

Randox offer a comprehensive panel of kidney health tests, working to ensure timely and accurate diagnosis of kidney function problems to combat patient challenges early.

For example, low levels of albumin indicate signs of kidney damage in the early stages when diagnosis is key. Testing for albumin can identify individuals with diabetic nephropathy (damage to the kidneys caused by diabetes) around 10 years earlier than standard protein tests. The Randox albumin test can therefore enable preventative measures to be taken to reduce your risk of developing kidney disease.

With early diagnosis we can improve patient treatment outcomes and reduce the number of people across the world suffering with kidney health problems.

If you are a clinician or lab interested in running renal function assays, download our Reagents Brochure or email reagents@randox.com

If you want to find out the status of your own Kidney Health, book a health check with Randox Health today.

 

 

Want to know more about Randox?

Contact us or visit our homepage to view more.


Chronic Kidney Disease

Chronic Kidney Disease

Early Multiplex Detection of Chronic Kidney Disease

Early Multiplex Detection of Chronic Kidney Disease from a Single Sample

  • null
    Simultaneous and quantitative detection of multiple serum biomarkers of kidney damage-related analytes
  • null
    Identifies the risk of CKD development / progression following an AKI episode
  • null
    Unique combination of analytes ensures better sensitivity and accuracy compared to traditional serum creatinine measurement
  • null
    Utilised widely in safety endpoint monitoring or drug-related renal toxicity during clinical trials
  • null
    The Randox CKD arrays utilises biomarkers to profile slow verus rapid CKD progression
  • null
    Biochip Technology effectively diagnoses early CKD, differentiates between stages and predicts a decline in a patient’s renal function

Chronic Kidney Disease is an abnormal kidney function and/ or structure, present for a minimum period of 3 months.

Typically diagnosed on the basis of serum creatine concentration, however, currently employed urine biomarkers do not reliably detect the early stages of CKD at which intervention could be more effective. Screening for CKD and any subsequent required treatments may then alter the course of early stage CKD and reduce complications and/or the associated health conditions.

Utilising patented Biochip Technology, the Randox Chronic Kidney Disease (CKD) arrays could improve patient risk stratification whilst monitoring the effectiveness of treatment. Diagnosis of CKD at early stages will allow earlier intervention for the treatment of kidney disease, and the prevention of further kidney damage.

Randox Chronic Kidney Disease (CKD) Array I (7-plex)

  • EGF
  • IL-8
  • sTNFR1
  • FABP1
  • sTNFR2
  • D-Dimer
  • MIP-1 alpha

EGF regulates renal cell proliferation, fibrosis and inflammation and is produced in response to renal injury.

IL-8 endothelial-derived chemokine involved in recruiting neutrophils to sites of injury and stimulating their response.

sTNFR1 is used to identify an increase in inflammatory conditions such as CKD.

FABP1 binds long-chain fatty acids, contributing to reducing oxidative stress in the kidneys.

sTNFR2 is used to identify an increase in inflammatory conditions such as CKD.

D-Dimer is a fibrin degradation product, and an index of both coagulation and fibrinolysis.

MIP-1 alpha plays a roles in inflammatory responses at sites of injury or infection.

Randox Chronic Kidney Disease (CKD) Array II (4-plex)

  • CRP
  • Cystatin C
  • C3a Des Arg
  • NGAL

CRP is an acute phase reactant involved in inflammation.

Cystatin C is well recognised marker of kidney filtration dysfunction and injury.

C3a des Arg is a representative of complement component C3a which produces local inflammatory responses.

NGAL is among the current state-of-the-art in CKD biomarkers.

The Evidence Investigator

Meet the Evidence Investigator

The Randox CKD arrays have both been developed for the Evidence Investigator, a semi-automated benchtop immunoassay analyser.

The CKD array’s would improve patient risk stratification whilst monitoring the effectiveness of treatment. Diagnosis of CKD at early stages will allow earlier intervention for the treatment of kidney disease, and the prevention of further kidney damage. Currently available for RUO.

Evidence Investigator

Want to know more?

Contact us or visit our Investigator Webpage


Chronic Kidney Disease

Chronic Kidney Disease

Early Multiplex Detection of Chronic Kidney Disease

Early Multiplex Detection of Chronic Kidney Disease from a Single Sample

  • null
    Simultaneous and quantitative detection of multiple serum biomarkers of kidney damage-related analytes
  • null
    Identifies the risk of CKD development / progression following an AKI episode
  • null
    Unique combination of analytes ensures better sensitivity and accuracy compared to traditional serum creatinine measurement
  • null
    Utilised widely in safety endpoint monitoring or drug-related renal toxicity during clinical trials
  • null
    The Randox CKD arrays utilises biomarkers to profile slow verus rapid CKD progression
  • null
    Biochip Technology effectively diagnoses early CKD, differentiates between stages and predicts a decline in a patient’s renal function

Chronic Kidney Disease is an abnormal kidney function and/ or structure, present for a minimum period of 3 months.

Typically diagnosed on the basis of serum creatine concentration, however, currently employed urine biomarkers do not reliably detect the early stages of CKD at which intervention could be more effective. Screening for CKD and any subsequent required treatments may then alter the course of early stage CKD and reduce complications and/or the associated health conditions.

Utilising patented Biochip Technology, the Randox Chronic Kidney Disease (CKD) arrays could improve patient risk stratification whilst monitoring the effectiveness of treatment. Diagnosis of CKD at early stages will allow earlier intervention for the treatment of kidney disease, and the prevention of further kidney damage.

Randox Chronic Kidney Disease (CKD) Array I (7-plex)

  • EGF
  • IL-8
  • sTNFR1
  • FABP1
  • sTNFR2
  • D-Dimer
  • MIP-1 alpha

EGF regulates renal cell proliferation, fibrosis and inflammation and is produced in response to renal injury.

IL-8 endothelial-derived chemokine involved in recruiting neutrophils to sites of injury and stimulating their response.

sTNFR1 is used to identify an increase in inflammatory conditions such as CKD.

FABP1 binds long-chain fatty acids, contributing to reducing oxidative stress in the kidneys.

sTNFR2 is used to identify an increase in inflammatory conditions such as CKD.

D-Dimer is a fibrin degradation product, and an index of both coagulation and fibrinolysis.

MIP-1 alpha plays a roles in inflammatory responses at sites of injury or infection.

Randox Chronic Kidney Disease (CKD) Array II (4-plex)

  • CRP
  • Cystatin C
  • C3a Des Arg
  • NGAL

CRP is an acute phase reactant involved in inflammation.

Cystatin C is well recognised marker of kidney filtration dysfunction and injury.

C3a des Arg is a representative of complement component C3a which produces local inflammatory responses.

NGAL is among the current state-of-the-art in CKD biomarkers.

The Evidence Investigator

Meet the Evidence Investigator

The Randox CKD arrays have both been developed for the Evidence Investigator, a semi-automated benchtop immunoassay analyser.

The CKD array’s would improve patient risk stratification whilst monitoring the effectiveness of treatment. Diagnosis of CKD at early stages will allow earlier intervention for the treatment of kidney disease, and the prevention of further kidney damage. Currently available for RUO.

Evidence Investigator

Want to know more?

Contact us or visit our Investigator Webpage


Early Detection of Acute Kidney Injury in COVID-19 patients

Randox Biosciences          Acute Kidney Injury          COVID-19

15 July 2020

 

The Importance of Early Detection of Acute Kidney Injury in COVID-19 patients

Randox are proud to provide an early detection assay, capable of detecting Acute Kidney Injury in COVID-19 positive patients. AKI is an innovative diagnostic tool with the ability to identify four early and highly sensitive markers of kidney injury.

The National Institute for Health and Care Excellence has highlighted that is important that COVID-19 patients are assessed for AKI on admission to hospital or transfer, monitored for AKI throughout their stay and that AKI is managed appropriately if it develops. (NICE, 2020)

The novel test, which includes biomarkers recommended by the U.S. Food and Drug Administration and the European Medicines Agency detects KIM-I, NGAL, Cystatin C, and Clusterin.

Kidney failure associated with COVID-19 is emerging as a common side effect with further studies underway. Early detection to prevent further renal damage, is vital for an individual’s long-term health, wellbeing and overall survival.

The biomarkers on the Randox AKI Biochip have been identified as more sensitive than traditional testing methods, which, based on urine output and levels of serum creatinine, are grossly insensitive and not specific for the accurate diagnosis and monitoring of AKI.

The Randox AKI assay provides results in 2.5 hours. The new testing panel also facilitates increased lab efficiency and reduced sample prep from the laboratory technician. Using just one urine sample, Randox’s patented Biochip Technology tests for all four AKI biomarkers simultaneously, resulting in time and cost saving benefits, which drive towards an increase in clinical performance.

For further information on our Acute Kidney Injury Array please visit the Randox Biosciences website.

For any other enquiries please email info@randoxbiosciences.com

RESEARCH

BIOPHARMA

CLINICAL LAB

BIOREAGENTS


DIKI: Drug Induced Kidney Injury Array from Randox Biosciences

Randox Biosciences introduces the innovative Randox Drug Induced Kidney Injury Array (DIKI). The new panels allow superior monitoring of nephrotoxicity for enhanced safety in drug development. It has been developed to identify four early stage markers of DIKI by screening for the biomarkers KIM-I, NGAL, Cystatin C, and Clusterin which have been identified as more sensitive than transitional testing methods to enhance accurate diagnosis of DIKI.

Our Biochip Array Technology enables multiplex immunoassay testing. The DIKI panel of 4 markers is combined on a single biochip, enabling simultaneous results from each patient sample, delivering:

  • Excellent inter-assay precision and required sensitivity
  • Superior specificity
  • Lower sample volume
  • Fast turnaround time
  • Safer drug development

 

With the number of hospitalised patients who develop a drug-induced renal problem due to the numbers of potent drugs have been added to the therapeutic arsenal in recent year1 – the DIKI can have a detrimental effect on a person’s health and wellbeing. Blakely stated that “drug-induced nephrotoxic contributes to 8 to 60% of all cases of AKI seen on the intensive care unit (ICU)”.2 Randox offers a 4-plex Drug Induced Kidney Injury test which detects early stage toxicity across the nephron, assisted through composite measurement. Earlier and more reliable detection of drug-induced kidney injury would improve clinical care and help to streamline drug-development. (Dieterle et al., 2010)3.

The poor sensitivity of serum creatinine for detecting and monitoring DIKI is well documented in academic journals. As a result, for early phase trials European Medicines Agency (EMA) and Food and Drug Administration (FDA) are encouraging the use of more novel urinary biomarkers alongside conventional safety monitoring. The new panel will be able to identify the levels of toxicity present in the kidneys which is classified as one of the most common side effects of drug development trials.

 

The new Randox Drug Induced Kidney Injury (DIKI) panel can help you conduct clinical trials safer and faster. For more information contact info@randoxbiosciences.com.

 

  1. https://www.ncbi.nlm.nih.gov/pubmed/2043284
  2. https://link.springer.com/chapter/10.1007/978-1-84628-937-8_3
  3. https://www.ncbi.nlm.nih.gov/pubmed/20458316

 

 

 

 

 

 

 

 


Kidney Testing on the Randox Biosciences Evidence Series

March is National Kidney Month, a full month dedicated to raising awareness about kidney disease.

There are two kinds of kidney disease; Chronic Kidney Disease (CKD) and Acute Kidney Injury (AKI).

Chronic Kidney Disease (CKD) affects 3 million people in the UK1. Chronic Kidney is defined as a condition that causes damage and stress on the kidneys, therefore decreasing the ability to keep your body healthy.

The kidneys play a vital role of removing any waste and extra water from the blood to form urine. The kidneys also make hormones that help control your blood pressure, make red blood cells, and keep your bones strong and healthy.2

It is crucial to look after your kidneys. If kidney disease gets worse, the excess waste can build to high levels in your blood, resulting in complications such as high blood pressure, anemia, weak bones, poor nutritional health and nerve damage, as well as increasing the risk of developing heart and blood vessel disease.

Chronic Kidney Disease if often caused by diabetes or having a high blood pressure, which can both be prevented by early detection and treatment. Without treatment the kidney disease will worsen resulting in kidney failure which requires dialysis or a kidney transplant to maintain life.

Chronic Kidney Disease I:

  • Fatty Acid Binding Protein I – FABPI
  • Soluble Tumour Necrosis Factor Receptor I – sTNFR I
  • Soluble Tumour Necrosis Factor Receptor II – sTNFR II
  • Macrophage Inflammatory Protein Iα – MIP-Iα
  • Interleukin-8 – IL-8
  • Epidermal Growth Factor – EGF
  • D-Dimer

Chronic Kidney Disease II:

  • Complement C3a Des Arginine – C3a des Arg
  • C-Reactive Protein – CRP
  • Neutrophil Gelatinase Associated Lipocalin – NGAL
  • Cystatin C

Acute Kidney Injury (AKI) is when your kidneys stop working properly. This is caused by reduced blood flow to the kidneys, which often happens as a complication of another serious disease.3 AKI affects one in five people admitted to hospital as an emergency, and is considered deadlier than a heart attack 2.

AKI can be reversible if found and treated quickly. Therefore, it is important, if someone has signs of having AKI, to get it treated promptly. Abnormal levels of salt and chemicals can build up in our bodies which causes organs to fail, resulting in the need for dialysis, or can even cause death. 3

  • Osteopontin – OPN
  • Serum creatinine – Creatinine
  • Serum cystatin-C – Cystatin-C
  • Kidney injury Molecule-I – KIM-I
  • Urinary neutrophil gelatinase associated lipocalin – NGAL

The Evidence Series of Immunoassay analysers contains four revolutionary Biochip Array Technology platforms including the Evidence, Evolution, MultiSTAT and the Investigator.

Randox’s renal panel is available on our Evidence Investigator Immunoassay Analyser, which is a multiplex testing platform allowing for the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample. It provides a unique platform for assessment of biological samples in a rapid, accurate and easy-to-use format.

For more information on any of the Evidence Series analysers, please visit https://www.randoxbiosciences.com/  or contact us at info@randoxbiosciences.com

  1. https://www.kidneycareuk.org/news-and-campaigns/facts-and-stats/
  2. https://www.niddk.nih.gov/health-information/kidney-disease/kidneys-how-they-work
  3. https://www.nhs.uk/conditions/acute-kidney-injury/

 

 

 

 

 

 

 


Is Biomarker Multiplexing the future of kidney disease screening?

Chronic Kidney Disease (CKD) is both a cause and a consequence of cardiovascular diseases, and is an increasing burden on global health. As diabetes, obesity and hypertension incidences continue to rise and the world’s population steadily ages, CKD’s prevalence is already estimated to be between 11% and 13% globally for all five KDOQI stages, with a majority in Stage 3 (about 90% of all stages).

With early stages of CKD being asymptomatic and current diagnostic tools (proteinuria determined by albumin to creatinine ratio and decreased renal function estimated from GFR using the CKD-EPI equation) are insufficiently sensitive to detect most cases up to stage 3, it is likely that the true prevalence of CKD is still underestimated. Therefore the need to improve both early diagnostics and overall CKD outcome is all the more critical.

Accordingly, biomarker research has been intense in the field of renal disease for at least 10 years with a number of promising candidates emerging, some now well-known by specialists: Cystatin C, NGAL or KIM-1 for example.

However, further novel biomarkers, assessed in combination using a properly developed multiplex assays can allow superior insight into CKD than what their individual performance could achieve.  This also largely stems from selecting the markers that are indicative of complementary mechanisms that contribute to the development of CKD.

When assayed together from a single serum sample and after combinatorial analysis has been applied, these biomarkers can open new avenues in the management of CKD, such as proper diagnosis of the condition from Stage 1, clear differentiation between stages and monitoring of the progression pace of the disease. Early screening of patients at risk of CKD is now within reach and it is expected that its systematic use will have a profound impact on health system economics.

Another area of interest in renal research is Acute Kidney Injury (AKI) which may arise as a result of cardiac surgery and can subsequently lead to CKD. AKI detection is also of significant interest in the field of drug development, where early stage toxicity is still a large cause of new drug marketing withdrawal. Hence selecting and qualifying kidney tissue damage biomarkers, and assembling them into a multiplex panel is a key priority to those involved in early stage clinical trials.

An AKI panel has been worked out using the same principles as those used in the development of the CKD panel: high individual diagnostic value and multiple, independent cellular targets. This panel is now ready for final clinical qualification and will be one of the first of several organ-targeted safety panels aiming to become standard for drug induced toxicity screening.

It is key to the adoption of multiplex testing that proper validation guidelines be published and that careful, matrix-based validation data is made available to potential users. It is essential that multiplexed testing comes to the front line of testing in the field, so it can deliver to its full potential and start translating into public health improvement and cost savings. Technology is ready, let’s make a start!

Dr Claire Huguet

Randox Biosciences – Head of Biomarkers

 

For further information about kidney disease screening from Randox Biosciences, please contact randoxpr@randox.com

 

 

 


Looking after your kidney health during your pregnancy

With this year’s World Kidney Day theme focusing on women’s health and in particular, their kidney health, the campaign is drawing attention to the need for a higher awareness, timely diagnosis and proper follow-up of kidney issues amongst women.

One key area being highlighted by the campaign is the close links between pregnancy and kidney health problems.  The two are intrinsically connected – with CKD considered a high-risk factor for problematic pregnancies and reduced fertility, and in turn, pregnancy-related complications, including preeclampsia, can increase the risk of kidney disease.

Although not commonly known, women who have Chronic Kidney Disease are at increased risk of hypertensive disorders and premature births – which can be devastating for all involved.

Women with Chronic Kidney Disease who become pregnant also usually have mild kidney dysfunction, the severity of which will depend on the stage the CKD is at.

It is clear therefore that there is a need for increased awareness of Chronic Kidney Disease in pregnancy, to timely identify its existence before conception, and to monitor its progress before, during and after birth.

With a comprehensive panel of kidney health tests, Randox are working to ensure timely diagnosis of kidney function problems, to ensure that necessary treatment is administered at the earliest possible stage, when it is most likely to be successful.

Pregnant women, or women hoping to get pregnant in the future, can therefore determine their kidney health and be empowered to embark upon the necessary lifestyle changes or treatment required to ensure a safe and healthy pregnancy.

For example, the Randox test for albumin, low concentrations of which are the earliest marker of kidney damage, can identify individuals with diabetic nephropathy (damage to the kidneys caused by diabetes) around 10 years earlier than standard protein tests. The Randox albumin test can therefore enable preventative measures to be taken to reduce your risk of developing kidney disease.

In addition to albumin, there are a number of other highly specific and sensitive tests for kidney health, which are available as part of a Randox Health Check at our Randox Health Clinics. These include;

  • Estimated Glomerular Filtration Rate, which is an equation that considers age, gender, blood and protein levels to determine how well the kidneys are functioning.
  • Creatinine, which is a waste product produced by muscle tissue, and removed by the kidneys. When kidney function is diminished, creatinine levels increase.
  • Other proteins within the body which should be filtered by the kidneys, and are therefore measured to determine kidney function, include;

–              Cystatin C

–              Beta-2-Microglobulin

–              Microalbumin, which is not usually found in urine, but can appear when normal kidney function is impaired.

  • Minerals processed by the kidneys and analysed by Randox Health include;

–              Magnesium

–              Calcium

–              Phosphate

–              Potassium

–              Sodium

Both World Kidney Day and Randox are working towards improving healthcare worldwide. With access to these high-performance kidney health tests, expectant mothers with kidney problems can be diagnosed early, before the condition develops into something more serious – keeping both you, and your baby healthy.

With early diagnosis we can improve patient treatment outcomes and reduce the number of people across the world suffering with kidney health problems.

 

If you are a clinician or lab interested in running renal function assays, download our Reagents Brochure or email reagents@randox.com

If you want to find out the status of your own Kidney Health, book a health check with Randox Health today. Speak to our team by phoning 0800 2545 130.

 

 

 


Randox Testing Services: Customer Testimonials from Ireland

At Randox Testing Services (RTS), we pride ourselves on helping our customers improve the health and safety of their working environment. Using our accurate and reliable testing methods and a range of additional services including training and policy reviews, we create tailored packages to meet the needs of our customers. We work with customers all over the world, but this month are highlighting the work we are doing across Ireland.

This month RTS will be attending the Northern Ireland Occupational Health, Hygiene and Wellbeing Conference at Titanic Belfast. This conference brings together companies from a range of industries all across Ireland to discuss the importance of employee health and wellbeing. As a company that began in Northern Ireland, RTS have always had strong connections with local businesses and are continually expanding our reach across Ireland.

Some of the companies with which we currently work, like GRAHAM construction, have recently provided feedback on our services. GRAHAM is based in Hillsborough, Co. Down and is a national construction, asset management and project investment business. They deliver services to a diverse range of clients from a network of regional offices, throughout the UK and Ireland.

GRAHAM Construction are proud to be partnered with Randox as their main Drug & Alcohol Service Provider. Over the years they have given a consistent, prompt, efficient, and professional service that delivered what was promised, when promised, to the proper agreed standards, which assists us in managing our relevant responsibilities with ease and confidence. I would have no hesitation in recommending them to others.”

This is great feedback to receive from such a reputable company who have a range of different testing needs. The construction industry is becoming more and more proactive when it comes to drug and alcohol testing. At RTS our experience working with GRAHAM and other major construction firms across the UK and Ireland means we are extremely well equipped to deal with the changing needs of this industry.

Another industry which requires a flexible and reliable drug and alcohol testing services provider is the aviation industry, especially when it comes to recruitment. We have been working with CAE Parc Aviation Services, the global leader in the provision of aviation personnel and support services to conduct pre-employment testing.

“We use Randox for Pre-Employment and Random Drug & Alcohol testing for select clients. We would happily recommend their services.”

Again, through working with various industries, the experience our staff possess is second to none. By qualifying the exact needs of our customers we create customised, cost-effective packages to ensure all testing needs are met.

As well as offering drug and alcohol testing services, our complete solution also includes a host of training, educational and consultancy services to equip our customers in tackling drug and alcohol misuse. Including comprehensive chain of custody training programs, which enables employers to conduct on-site collections to the same standard as a Randox Testing Services collection specialist.

The Henderson Group in Newtownabbey are another large company that has availed of the services offered by Randox Testing Services. The Henderson Group are the owners of the SPAR, EUROSPAR, ViVO, ViVOXTRA and ViVO Essentials franchises in Northern Ireland and have been distributing food and grocery-related products to the convenience retail sector for over 100 years.

“We switched provider for our Drug and Alcohol policy almost two years ago, moving to Randox.  The switchover was relatively seamless and the impact on our business has been positive.  Our tests are now all completed within target and we have realised a saving to boot.  We are glad we made the switch.”

 

 

Randox Testing Services is committed to tailoring our service to the needs of customers all over the world, and across the island of Ireland.

If your company would like to speak to us, please contact testingservices@randox.com

Alternatively you can contact David O’Regan, the Business Development Executive for Ireland directly: David.O’Regan@randox.com.

 

 


Request a meeting
×
Make an Enquiry - RX series
×
Make an Enquiry - Reagents
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Reagents
×
Make an Enquiry - Quality Control
×
Make an Enquiry - RIQAS
×
Make an Enquiry - RIQAS
×
Make an Enquiry - Quality Control
×
Make an Enquiry
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Biochip
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Molecular
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Future Diagnostics
×
Make an Enquiry - RX series (Product)
×
Make an Enquiry - Quality Control
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - RIQAS
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Por favor, introduzca sus datos para ver nuestro último seminario
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje Polityki Prywatności.
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności.
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności.
×
Wyślij zapytanie